Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer

2026-02-21 03:49:20

Roivant Sciences’ subsidiary Priovant Therapeutics announced positive Phase 2 results for brepocitinib in cutaneous sarcoidosis, a rare inflammatory skin disorder. This success, following a licensing deal with Pfizer, positions the dual JAK1 and TYK2 inhibitor for pivotal testing and adds to its blockbuster sales potential across multiple rare diseases, including dermatomyositis and non-infectious uveitis. The drug’s safety profile has been consistent, and it offers a crucial treatment option for conditions where current therapies are limited or carry significant risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes